Corline Pharma

Corline Biomedical is a Swedish biotechnology company that develops heparin-based surface coatings to improve the biocompatibility of medical devices and cell therapies. The company's core technology, the Corline Heparin Surface (CHS), mimics the natural lining of human blood vessels to prevent blood clotting and inflammatory reactions when foreign materials or cells are introduced into the body. Its lead pharmaceutical candidate, Renaparin, is currently in Phase 2 clinical trials for the prevention of delayed graft function in kidney transplantation. Additionally, Corline is advancing Cytoparin, a product designed to protect transplanted islet cells in the treatment of type 1 diabetes. The company also generates revenue by licensing its CHS technology to medical device manufacturers globally.